Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene-Edited immune cells take on Hard-to-Treat cancers

NCT ID NCT05795595

Disease control Sponsor: CRISPR Therapeutics AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new treatment called CTX131 for adults with advanced solid tumors that have not responded to standard therapies. The treatment uses donor immune cells that are gene-edited to target a protein called CD70 found on cancer cells. The study enrolled 19 people with several cancer types to check safety and whether the tumors shrink.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

19 people

The number who actually took part.

Started

Mar 2023

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Age ≥18 years. 2. Unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma. 3. Eastern Cooperative Oncology Group performance status 0 or 1. 4. Adequate renal, liver, cardiac and pulmonary organ function. 5. Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX131 infusion. Key Exclusion Criteria: 1. Prior treatment with anti-CD70 targeting agents 2. History of certain central nervous system (CNS), cardiac or pulmonary conditions. 3. Presence of uncontrolled bacterial, viral, or fungal infection. 4. Active HIV, hepatitis B virus or hepatitis C virus infection. 5. Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy. 6. Women who are pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma carcinoma of esophagus cervical carcinoma Esophageal Neoplasms malignant pleural mesothelioma Mesothelioma, Malignant nonpapillary renal cell carcinoma pancreatic adenocarcinoma renal cell carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical carcinoma Clear cell renal cell carcinoma Esophageal carcinoma Malignant pleural mesothelioma Pancreatic adenocarcinoma

Contacts and locations

Locations

  • Research Site 1

    Nashville, Tennessee, 37203, United States

  • Research Site 2

    St Louis, Missouri, 63110, United States

  • Research Site 3

    Duarte, California, 91010, United States

  • Research Site 4

    Durham, North Carolina, 27710, United States

  • Research Site 5

    Houston, Texas, 77030, United States

  • Research Site 6

    Boston, Massachusetts, 02215, United States

  • Research Site 7

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.